Zynerba Pharmaceuticals Liabilities 2024

Zynerba Pharmaceuticals Aktienanalyse

What does Zynerba Pharmaceuticals do?

Zynerba Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe central nervous system disorders. The company was founded in 2007 and is headquartered in Devon, Pennsylvania, USA. The history of Zynerba Pharmaceuticals dates back to the discovery by Dr. Magid Abou-Gharbia, who led a team of scientists that developed a method for transporting cannabinoids through the blood-brain barrier. This groundbreaking discovery led to the formation of Zynerba Pharmaceuticals with the goal of developing novel cannabinoid-based therapies. Zynerba Pharmaceuticals' business model is based on the development of medical compounds derived from the cannabis plant. These compounds, known as cannabinoids, have the potential to treat a variety of different conditions related to the central nervous system. The company's strategy is to deliver these compounds in the form of transdermal patches to ensure optimal dosage and absorption by the body. Zynerba Pharmaceuticals is divided into different divisions that focus on specific conditions. The company's main division is the development of therapies for epilepsy based on the cannabinoid Zygel. Zygel is a synthetic cannabinoid administered as a transdermal patch and has high bioavailability. The patch is applied to the skin and delivers a precise dosage of Zygel to reduce seizures in patients with various forms of epilepsy. In addition, Zynerba Pharmaceuticals is working on therapies for neuropsychiatric disorders such as Fragile X syndrome, autism spectrum disorders, and schizophrenia. The company has a promising development pipeline and is currently involved in various clinical trials. The company has achieved many milestones and formed important partnerships to support its innovative research and development. In 2019, Zynerba Pharmaceuticals partnered with the Japanese company Daiichi Sankyo to expand its development pipeline. In summary, Zynerba Pharmaceuticals Inc offers a promising business model for the development of therapies for severe central nervous system disorders based on cannabinoids. The company has a promising development pipeline and has already formed important partnerships to support its research and development. Zynerba Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Zynerba Pharmaceuticals's Liabilities

Zynerba Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Zynerba Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Zynerba Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Zynerba Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Zynerba Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Zynerba Pharmaceuticals Stock

What is the level of liabilities of Zynerba Pharmaceuticals this year?

Zynerba Pharmaceuticals has a debt balance of 9.29 M USD this year.

What were the liabilities of Zynerba Pharmaceuticals compared to the previous year?

The liabilities of Zynerba Pharmaceuticals have increased by -9.42% dropped compared to the previous year.

What are the consequences of high debt for investors of Zynerba Pharmaceuticals?

High liabilities can pose a risk for investors of Zynerba Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Zynerba Pharmaceuticals?

Low liabilities mean that Zynerba Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Zynerba Pharmaceuticals affect the company?

An increase in liabilities of Zynerba Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Zynerba Pharmaceuticals affect the company?

A decrease in the liabilities of Zynerba Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Zynerba Pharmaceuticals?

Some factors that can influence the liabilities of Zynerba Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Zynerba Pharmaceuticals so important for investors?

The liabilities of Zynerba Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Zynerba Pharmaceuticals take to modify the liabilities?

To change its liabilities, Zynerba Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Zynerba Pharmaceuticals pay?

Over the past 12 months, Zynerba Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zynerba Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Zynerba Pharmaceuticals?

The current dividend yield of Zynerba Pharmaceuticals is .

When does Zynerba Pharmaceuticals pay dividends?

Zynerba Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Zynerba Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zynerba Pharmaceuticals located?

Zynerba Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zynerba Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zynerba Pharmaceuticals from 6/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.

When did Zynerba Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/26/2024.

What was the dividend of Zynerba Pharmaceuticals in the year 2023?

In the year 2023, Zynerba Pharmaceuticals distributed 0 USD as dividends.

In which currency does Zynerba Pharmaceuticals pay out the dividend?

The dividends of Zynerba Pharmaceuticals are distributed in USD.